{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 28,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines study design for Part 1, 2, and 3 of a clinical trial for chronic hepatitis B (cHBV).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/10",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.33,
        "y": 0.23
      },
      "kind": "list",
      "text": "E: 60mg Q4W HBV DNA-; F: 60mg Q8W HBV DNA-; G: 90mg Q8W + TDF HBV DNA+; I: 90mg Q8W HBV DNA-; J: 90mg Q12W HBV DNA-; K: 90mg Q8W HBV DNA-, HBeAg+ only",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aae9f74d-ddf4-4fac-af5e-63e46fed0ca9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.04,
        "y": 0.54
      },
      "kind": "list",
      "text": "Imdusiran monotherapy conclusions: Robust HBsAg declines across all cohorts; HBV DNA declines in HBV DNA+ patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b30d5381-488a-493a-8cfe-0bbeda31d275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Part 1 & 2: Single-ascending dose",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb0b2dcb-65ec-476b-ae41-a41c4fbe122e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.33,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "HBeAg: HBV E antigen | TDF: tenofovir disoproxil fumarate. Data presented at EASL 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cff82afc-931f-493c-ba93-47ec5d4324c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-729-001 Phase 1a/1b Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "064ee0c6-960c-4602-abe3-7188382bce52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.33,
        "y": 0.17
      },
      "kind": "title",
      "text": "Part 3: Multiple Ascending Dose in cHBV Patients",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21810b35-6ef5-4b50-b9eb-40ef4360770c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "8558af21-b173-40d9-bee7-cbb86e4f3ca4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Arbutus Biopharma's pipeline, including Imdusiran, AB-161, and AB-101, as a promising approach to treating HBV",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "cf0f4444-bb37-4efd-b316-e8da602c5aea",
      "evidence": "The deck presents data and results from clinical trials for Imdusiran and other pipeline assets",
      "position": 1,
      "objective": "Showcase Arbutus Biopharma's pipeline as a solution to the HBV problem",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}